logo for Halozyme Therapeutics

Halozyme Therapeutics

Manufacturing · California, United States · 373 Employees

View Company Info for Free

About

Headquarters

12390 El Camino Real, San Diego, California, 92...

Phone Number

(858) 794-8889

Revenue

$947.4 Million

Stock Symbol

HALO

Industry

Pharmaceuticals Healthcare

Most Recent Scoops

Earnings
reported that BMS aims to convert 30% to 40% of the current Opdivo business to subcutaneous, with Opdivo sales projected at $10 billion in 2028. The company projects to deliver $1 billion in royalty revenue in 2027, with current projections of $725 million to $750 million this year, and $1.1 to $1.5 billion in 2027.
Earnings
reported that Darzalex subcutaneous with ENHANZE has 95% share of sales in the US, enabling deeper penetration into front and second line treatment populations. Analysts expect continued strong year-over-year growth, projecting greater than $17 billion in sales in 2028, with Halozyme Therapeutics receiving on average a mid-single digit royalty on net sales.
See all scoops

Highlights

$1.1B

Total Funding Amount

$400M

Most Recent Funding Amount

10

Number of Funding Rounds

View details

Who is Halozyme Therapeutics

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companiesRead more
Halozyme Therapeutics's Social MediaPopular SearchesHalozyme Therapeutics IncHalozyme Therapeuticshalozyme IncHalozymeHalzyme Technologies IncSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: HALOShow more

Halozyme Therapeutics Org Chart

PhoneEmail
Nicole LaBrosse

Senior Vice President, Chief Financial Office...

PhoneEmail
Amy Fox

Vice President, Chief Human Resources Officer

PhoneEmail

PhoneEmail

Is Halozyme Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Halozyme Therapeutics

Compare insights from companies similar to Halozyme Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Halozyme Therapeutics

$947.4M
373
Placeholder for Top Executive
$61.5M
241
Placeholder for Top Executive
<$5M
127
Placeholder for Top Executive
Illustration of an envelope

Halozyme Therapeutics financials insights

Gather financial insights about Halozyme Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

Halozyme Therapeutics Employee Growth Rate

Graph showing projected employee growth data for Halozyme Therapeutics

View Halozyme Therapeutics’s full employee growth data

Percentage of growth

1st year Mask

2nd year Mask

Halozyme Therapeutics Tech Stack

A closer look at the technologies used by Halozyme Therapeutics

Most Recent Scoops

Earnings
reported that BMS aims to convert 30% to 40% of the current Opdivo business to subcutaneous, with Opdivo sales projected at $10 billion in 2028. The company projects to deliver $1 billion in royalty revenue in 2027, with current projections of $725 million to $750 million this year, and $1.1 to $1.5 billion in 2027.
Earnings, Business Intelligence, Analytics & Insights, Pharmaceuticals, Finance
Earnings
reported that Darzalex subcutaneous with ENHANZE has 95% share of sales in the US, enabling deeper penetration into front and second line treatment populations. Analysts expect continued strong year-over-year growth, projecting greater than $17 billion in sales in 2028, with Halozyme Therapeutics receiving on average a mid-single digit royalty on net sales.
Earnings, Business Intelligence, Analytics & Insights, Pharmaceuticals, Finance
Project
Halozyme Therapeutics announced expectations for a slow start to new product launches, typically taking 6-9 months in the US and 12+ months outside the US before significant uptake. The company expects rapid adoption of Opdivo subcutaneous in the UK and multiple European markets, similar to historical trends with products like Herceptin and MabThera.
Business Intelligence, Analytics & Insights, Pharmaceuticals
Project
Halozyme Therapeutics announced that Ocrevus subcutaneous treatment time has been reduced to just 10 minutes compared to multiple hours for IV, with patients reporting a 92% satisfaction rate. The company also introduced Rozanolixizumab, Efgartigimod, and Opdivo subcutaneous, offering patients the potential to receive their treatment subcutaneously in minutes.
Pharmaceuticals, Patient Experience
Earnings
Earnings, Business Intelligence, Analytics & Insights, Product Launch, Pharmaceuticals, Finance
See more scoops

Halozyme Therapeutics News & Media

Read more news

Top Companies in United States

Top 10 companies in United States by revenue

Top 10 companies in United States by number of employees

Top 10 companies in United States by total funding amount

See top companies

Frequently Asked Questions Regarding Halozyme Therapeutics

Where is Halozyme Therapeutics located?
Halozyme Therapeutics's headquarters are located at 12390 El Camino Real, San Diego, California, 92130, United States
What is Halozyme Therapeutics's phone number?
Halozyme Therapeutics's phone number is (858) 794-8889
What is Halozyme Therapeutics's stock symbol?
Halozyme Therapeutics's stock symbol is HALO
What is Halozyme Therapeutics's official website?
Halozyme Therapeutics's official website is www.halozyme.com
What is Halozyme Therapeutics's Revenue?
Halozyme Therapeutics's revenue is $947.4 Million
What is Halozyme Therapeutics's SIC code?
Halozyme Therapeutics's SIC: 28,283
What is Halozyme Therapeutics's NAICS code?
Halozyme Therapeutics's NAICS: 32,325
How many employees does Halozyme Therapeutics have?
Halozyme Therapeutics has 373 employees
What industry does Halozyme Therapeutics belong to?
Halozyme Therapeutics is in the industry of: Pharmaceuticals, Healthcare
What is Halozyme Therapeutics competition?
Halozyme Therapeutics top competitors include: Puma Biotechnology, Harbour BioMed, INOVIO, Atara Biotherapeutics
What companies has Halozyme Therapeutics acquired?
Halozyme Therapeutics has acquired the companies: Evotec, Aptuit, InfoPro Solutions, ALMEDICA
What technology does Halozyme Therapeutics use?
Some of the popular technologies that Halozyme Therapeutics uses are: Q4, DocuSign, WordPress.org, reCAPTCHA
Who is the CFO of Halozyme Therapeutics?
Halozyme Therapeutics's CFO is Nicole LaBrosse
How do I contact Halozyme Therapeutics?
Halozyme Therapeutics contact info: Phone number: (858) 794-8889 Website: www.halozyme.com
What does Halozyme Therapeutics do?

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected... drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.Read More

What are Halozyme Therapeutics social media links?
Halozyme Therapeutics Linkedin page Halozyme Therapeutics Twitter page Halozyme Therapeutics Facebook page
How much funding has Halozyme Therapeutics raised to date?
Halozyme Therapeutics has raised $1.1 Billion in 10 funding rounds
When was the last funding round for Halozyme Therapeutics?
Halozyme Therapeutics closed its last funding round on Nov 13, 2019 with the amount of $400 Million
Who invested in Halozyme Therapeutics?
Halozyme Therapeutics has 12 investors including Undisclosed, Undisclosed, Baxter Healthcare Corporation and New River Management.
Is Halozyme Therapeutics a public company?
Yes, Halozyme Therapeutics is a public company and is traded under the symbol HALO
See more information about Halozyme Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.